Sutro Biopharma (STRO) Restructuring Costs (2025)

Sutro Biopharma's (STRO) quarterly Restructuring Costs came in at $1.6 million in Q4 2025, down 78.39% quarter-over-quarter from $7.3 million in Q3 2025.

Sutro Biopharma (STRO) Restructuring Costs (2025) Analysis & Trends

Sutro Biopharma has disclosed Restructuring Costs across 1 years of filings, most recently posting $1.6 million for Q4 2025.

  • Restructuring Costs for Q4 2025 came in at $1.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $26.1 million (changed N/A YoY), and the FY2025 annual result was $26.1 million, changed N/A from the prior year.
  • Restructuring Costs came in at $1.6 million for Q4 2025 at Sutro Biopharma, down from $7.3 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $13.0 million in Q2 2025 to a low of $1.6 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Sutro Biopharma 252.04 Mn 252.04 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.58 Mn
Sep 30, 2025 7.31 Mn
Jun 30, 2025 13.01 Mn
Mar 31, 2025 4.26 Mn